![What's in a name? Renaming 'NAFLD' to 'MAFLD' - Fouad - 2020 - Liver International - Wiley Online Library What's in a name? Renaming 'NAFLD' to 'MAFLD' - Fouad - 2020 - Liver International - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/cb84ed96-620a-4937-bbd3-007dbff23aef/liv14478-fig-0001-m.jpg)
What's in a name? Renaming 'NAFLD' to 'MAFLD' - Fouad - 2020 - Liver International - Wiley Online Library
![Hormone identified that limits liver fibrosis - Potential applications for treating nonalcoholic steatohepatitis, cirrhosis - | Research at Kobe Hormone identified that limits liver fibrosis - Potential applications for treating nonalcoholic steatohepatitis, cirrhosis - | Research at Kobe](https://www.kobe-u.ac.jp/images/research_at_kobe_en/news/2016_10_13_01-1.jpg)
Hormone identified that limits liver fibrosis - Potential applications for treating nonalcoholic steatohepatitis, cirrhosis - | Research at Kobe
![In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications - ScienceDirect In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2589004221015194-fx1.jpg)
In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications - ScienceDirect
![First Wave of Novel Drugs for NASH Does Not Live Up to Expectations, Clinical Pharmacy Service's Pipeline Monitoring Team Finds | ForHealth Consulting First Wave of Novel Drugs for NASH Does Not Live Up to Expectations, Clinical Pharmacy Service's Pipeline Monitoring Team Finds | ForHealth Consulting](https://forhealthconsulting.umassmed.edu/wp-content/uploads/2022/12/NASH.png)
First Wave of Novel Drugs for NASH Does Not Live Up to Expectations, Clinical Pharmacy Service's Pipeline Monitoring Team Finds | ForHealth Consulting
![IJMS | Free Full-Text | Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC IJMS | Free Full-Text | Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC](https://www.mdpi.com/ijms/ijms-22-04495/article_deploy/html/images/ijms-22-04495-g001.png)
IJMS | Free Full-Text | Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
![Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)](https://publinestorage.blob.core.windows.net/b19a48f4-4061-46e6-b55c-8231ba2180a0/jcth-9-939-ga.jpg)
Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
![New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis | SpringerLink New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs43440-019-00020-1/MediaObjects/43440_2019_20_Fig1_HTML.png)